Core Viewpoint - PolyPid Ltd. has initiated a New Drug Application (NDA) submission for D-PLEX₁₀₀ to the FDA for preventing surgical site infections in colorectal surgery, with completion expected in the second quarter of 2026 [2][4]. Group 1: NDA Submission Details - The NDA is submitted under the FDA's Fast Track designation, allowing for a rolling review process [3]. - The initial submission includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections, with the clinical section to follow in the second quarter of 2026 [3]. Group 2: Product Information - D-PLEX₁₀₀ is designed to provide prolonged and controlled antibacterial activity at the surgical site, utilizing PolyPid's Kynatrix delivery technology to release doxycycline over 30 days [5]. - The product demonstrated a statistically significant 60% relative risk reduction in surgical site infection incidence in the Phase 3 SHIELD II trial [5]. Group 3: Company Overview - PolyPid Ltd. focuses on developing long-acting, controlled-release drugs to address unmet medical needs across various therapeutic areas, including surgical care and metabolic diseases [6]. - The company aims to redefine therapy performance and enhance patient care standards through innovation [6].

Core Insights - SpyGlass Pharma is advancing its BIM-IOL System, having initiated two Phase 3 trials and successfully completed an IPO to fund these developments [2][7][10] - The company aims to provide long-term, eye drop-free therapy for approximately one million glaucoma and ocular hypertension patients undergoing cataract surgery in the U.S. each year [2] Business Highlights - The BIM-IOL System showed positive topline results in its Phase 1/2 trial, with a 34% and 42% reduction in mean intraocular pressure (IOP) for high and low dose groups respectively, compared to a 35% reduction in the control group [3] - 98% of patients in the high dose group and 96% in the low dose group were free from topical IOP-lowering medications 12 months post-surgery [3] - The system demonstrated improved visual performance, with 100% of participants achieving 20/32 or better best corrected distance visual acuity (BCDVA) [3] Financial Results - As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $107.4 million, excluding IPO proceeds [10] - Research and development expenses increased to $7.7 million for Q4 2025 and $29.2 million for the full year, compared to $5.7 million and $20.0 million in 2024 [11] - The net loss for Q4 2025 was $12.6 million, or ($5.72) per share, compared to a loss of $8.4 million, or ($4.58) per share in Q4 2024 [13] Upcoming Milestones - The company plans to initiate a first-in-human trial for the Bimatoprost Drug Ring System (BIM-DRS) in the second half of 2026 [17] - Full enrollment for the ongoing Phase 3 trials of the BIM-IOL System is expected by 2027 [7] Corporate Developments - SpyGlass Pharma completed its IPO in February 2026, raising $172.5 million, which will fund operations through 2028 [7][10] - The company appointed new leadership, including Habib Dable to the board and Jean-Frédéric Viret as CFO, enhancing its management team [16]